Improving care of hospitalized patients with HIV in Tanzania

Researchers at Weill Cornell Medicine have shown that three months of social worker follow-up support to people hospitalized with HIV in Tanzania had health benefits at low cost.

Linguistic clues can help detect mild cognitive impairment

Older adults with impaired memory exhibit selective language deterioration – a finding that could lead to earlier detection and ultimately more effective treatment of Alzheimer’s disease.

Higher bacterial counts detected in single-serving milks

After examining pasteurized single-serving milk cartons, Cornell food scientists found bacterial counts two weeks after processing were higher than in larger containers from the same facilities.

microRNA predicts severe Crohn’s disease in children

Researchers comparing intestinal samples of children with Crohn’s disease and healthy children found one molecule that shows significant differences between the two groups.

Deciphering the male breast cancer genome

Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators.

Filament formation enables cancer cells’ glutamine addiction

Blocking the formation of filaments – multi-enzyme structures that fuel cancer activity – may offer new ways to control cancer cell proliferation, according to a new study led by Cornell researchers.

Digital campus guide makes Cornell Tech more accessible

Cornell Tech has launched a new digital guide highlighting the many cultural attributes of its campus on Bloomberg Connects, the free arts and cultural app created by Bloomberg Philanthropies.

Grad student grants support sustainability, biodiversity

Awarded graduate students will study sustainability, biodiversity, accelerating energy transitions, advancing human health, increasing food security or addressing climate change.

Drug-resistant TB responds rapidly to bedaquiline-based therapy

Patients who have drug-resistant tuberculosis have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine.